Full requirements: Wegovy for Weight Loss (1 plan type)›
Applies to Medicaid plans.
Covered with requirements
See the original policy for clinical requirements.
Documentation to bring
Weight Management Agents SA Form
Policy note: Wegovy is listed as a Non-Preferred agent under the Weight Management Agents CLOSED CLASS. The SA criteria reference a 'Weight Management Agents SA Form' for full clinical criteria details, which are not reproduced in this document. The document also references separate SA forms for CV risk reduction, OSA, and MASH indications. Authorization length is 'as indicated on fax form'.
Policy effective April 1, 2026 · verified June 4, 2026 · source: V Amed Pdl List Criteria 20260401 V6
· View policy document (PDF)
Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)›
Applies to Medicaid plans.
Covered with requirements
What you need to qualify
Established cardiovascular disease
Documentation to bring
GLP-1 Receptor Agonist For Cardiovascular Risk Reduction in Members with Obesity or Overweight SA Form
Policy note: The document references a separate SA form titled 'GLP-1 Receptor Agonist For Cardiovascular Risk Reduction in Members with Obesity or Overweight SA Form'. The indication is identified as cardiovascular risk reduction in members with obesity or overweight. Detailed clinical criteria are contained in the referenced fax form, not reproduced here. The document notes 'The selected GLP-1 Receptor Agonist is injectable brand Wegovy' for this indication. Authorization length is 'as indicated on fax form'.
Policy effective April 1, 2026 · verified June 4, 2026 · source: V Amed Pdl List Criteria 20260401 V6
· View policy document (PDF)
Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)›
Applies to Medicaid plans.
Covered with requirements
What you need to qualify
Confirmed MASH diagnosis
Documentation to bring
GLP-1 Receptor Agonists for Metabolic Dysfunction-Associated Steatohepatitis SA Form
Policy note: The document references a separate SA form titled 'GLP-1 Receptor Agonists for Metabolic Dysfunction-Associated Steatohepatitis SA Form'. Detailed clinical criteria are contained in the referenced fax form and not reproduced in this PDL document. Authorization length is 'as indicated on fax form'. The document notes 'The selected GLP-1 Receptor Agonist is injectable brand Wegovy'.
Policy effective April 1, 2026 · verified June 4, 2026 · source: V Amed Pdl List Criteria 20260401 V6
· View policy document (PDF)
Yes. Virginia Medicaid covers Wegovy for weight loss with prior authorization. Other policy requirements and your plan's benefits also apply.
How current is this information?
The oldest review date among the policies on this page is June 4, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.
Card and program names on file in Virginia
These names map to Virginia Medicaid, including older names and spelling variants. This is not a list of plans currently accepting members.